More clinically relevant models are urgently needed for preclinical drug development. This webinar discusses the development and characterization of HUB Organoid models, and how these are applied to OcellO’s screening
platform to offer services to study and advance therapeutics for oncology, and immuno-oncology. The speakers describe HUB Organoid features that preserve the genetic and phenotypic characteristics of the original tumor, and provide insight into the
unique high-throughput, high content imaging-based in vitro system for screening the efficacy of (immuno)oncological drugs and exemplify the use of the system to prioritize cancer drug candidates to enter the clinic.
- Features and advantages of HUB Organoids™
- Why HUB Organoids are considered to be superior 3D preclinical model systems
- How to apply HUB Organoids to fundamental research and infectious diseases
- Impact and possibilities of HUB Organoids in oncology and immuno-oncology drug discovery
- OcellO’s 3D in vitro screening platform – value of combining 3D in vitro systems with high-throughput and high-content analysis
- How the use of OcellO 3D in vitro oncology assay and HUB CRC Organoids can advance preclinical candidates to the clinic
- How OcellO’s immuno-oncology assay is changing the possibilities of preclinical translation of immunotherapies
Who Should Attend:
- Drug developers interested in understanding the benefit of (tumor) organoids compared to standard 3D systems
- Decision makers from biotech and pharmaceutical companies who are looking to enhance the translatability of their early stage drug development programs
- Researchers interested in learning about HUB Organoids and their predictive power
- Biotech and pharma companies interested in high-throughput, high content imaging-based in vitro system for screening the efficacy of (immuno)oncological drugs
Bram Herpers, PhD
Senior Director, Oncology, OcellO BV
Bram Herpers was trained as a cell biologist and held positions in MRC-FGU in Oxford, Utrecht and Leiden University in microscopy, toxicology and cancer research. During his PostDoc at Leiden University he developed and implemented multiple high throughput, high content image-based screening methods for compounds in the Division of Toxicology. In 2013 Bram joined OcellO as Chief Operations Officer and currently is the Senior Director and head of Oncology team. His expertise in advanced microscopy and high content screening is complemented by an excellent track record of project management. He led an FP7 project supresSTEM to develop OcellO’s organoid screening platform and identified a drug for colon cancer now in clinical trials. Bram leads the development of oncology assay to test cancer therapies on OcellO’s 3D in vitro platform, to help biotech and pharma companies discover the full potential of their compounds.
Lidia Daszkiewicz, PhD
Senior Director, Immuno-Oncology, OcellO BV
Lidia is Senior Director and Head of Immuno-Oncology department at OcellO. She is passionate about bringing in vitro solutions for preclinical testing to cancer immunotherapy developers. Lidia has a background in Molecular Biology; she obtained her PhD in the department of Oncology and Immunology at the Autonoma University in Madrid, Spain. During her Postdoc at the Vrije Universiteit in Brussels, Belgium she specialized in cancer immunology and subsequently she switched from academia to industry and became interested in turning the discoveries into products that can make a real difference for cancer patients. In her role as immuno-oncology team leader at OcellO she manages the development of proprietary tumor-immune cell co-culture assay to test immunotherapies on OcellO’s in vitro 3D platform. With her business development experience and scientific expertise, she has supported multiple pharma and biotech companies globally in gaining a deeper understanding of the mechanisms that govern anti-tumor immune responses and the potential of their compounds have to enhance this process.
Robert Vries, PhD
CEO, Hubrecht Organoid Technology (HUB)
Robert Vries received his PhD in Biochemistry from the Leiden University Center on a molecular study of oncogenic
transformation. He continued his scientific career as Postdoc at Stanford University (USA). Upon his return to the
Netherlands, he joined the group of Hans Clevers at the Hubrecht Institute studying adult stem cells. In the group
of Hans Clevers, he was part of the team that developed the ground-breaking technology that allowed the
expansion of adult stem cells in vitro. The so-called Organoid Technology became the basis of the company Hubrecht Organoid Technology (HUB) of which he is currently the CEO.